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Abstract New strategy of cancer’s targeting treatment is
combining monoclonal antibodies with chemotherapeutic
agents. An important goal of targeted therapy appears to be
a transmembrane glycoprotein type I—mucin 1 (MUC1),
which is overexpressed in tumors of epithelial origin,
especially in breast cancer. The goal of the study was to
check the effect of monoclonal antibody against MUC1
with novel platinum(II) complex (Pt12) on selected aspects
of apoptosis in human MDA-MB-231 breast cancer cells.
The number of apoptotic and necrotic cells was measured
using annexin V binding assay. The decrease of mito-
chondrial membrane potential (MMP) and DNA fragmen-
tation was analyzed. Finally, the influence of novel
platinum(II) complex (Pt12) used with anti-MUC1 on the
concentration of selected markers of apoptosis such as Bax,
caspase-8, -9, and caspase-3 was performed using ELISA.
The results from combined treatment were compared with
those obtained using monotherapy. In our study, we proved
that anti-MUC1 used in combination with Pt12 strongly
induced apoptosis in MDA-MB-231 breast cancer cell line.
The effect was stronger than treatment with Pt12, cisplatin,
anti-MUC1, and anti-MUC1 used with cisplatin. We also
observed the highest decrease of MMP and the strongest
DNA fragmentation after such a combined treatment. The
results obtained from ELISA showed increased concen-
tration of Bax, caspases-8, -9, -3 compared to monother-
apy. Our study proved that Pt12 together with anti-MUC1
strongly induced apoptosis in estrogen-negative breast
cancer cell line (MDA-MB-231). The apoptosis may go
through extrinsic pathway associated with caspase-8 as
well as intrinsic pathway connected with caspase-9.
Keywords Anti-MUC1  Anticancer drugs  Platinum
complexes  Targeted therapy  Apoptotic markers
Introduction
Currently, only 20–75 % of patients with cancer (me-
lanoma 4–12 %) correspond to the standard treatment. The
specific targeted therapy is one of the greatest achieve-
ments of medicine in the last decade. New strategy of
cancer’s targeting treatment is combining monoclonal
antibodies with chemotherapeutic agents. An important
goal of targeting therapy appears to be a transmembrane
glycoprotein type I—mucin 1 (MUC1) which is overex-
pressed in tumors of epithelial origin, especially in breast
cancer [1–3]. In many tumor types, MUC1 expression
correlates with aggressive, metastatic disease, poor
response to therapy, and poor survival [4]. MUC1 was
ranked by the National Cancer Institute as the second most
promising candidate tumor antigen with a high clinical
potential [5, 6]. MUC1 is also involved in the phenomenon
of drug resistance and in the inhibition of induction of
apoptosis. Increased expression of MUC1 induces thyroid
cancer cell resistance to cisplatin, docetaxel and doxoru-
bicin [7] and it induces the resistance to trastuzumab in
breast cancer cells [8]. MUC1 inhibits the release of
apoptotic markers and activation of caspase-3 in colon
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cancer cells treated with cisplatin [9]. MUC1 cytoplasmic
domain inhibits the intrinsic apoptotic pathway by regula-
tion of various signaling pathways associated with p53,
FOXO3a, c-Abl, IkB complex, FADD, or Bax. Mucin
domain that interacts with the pro-apoptotic protein Bax in
the cytoplasm and mitochondria blocks its dimerization
and leads to the inhibition of the releasement of cyto-
chrome c [10]. The cytoplasmic domain of MUC1 may
communicate with caspase-8 and Fas receptor thereby
blocking activation of extrinsic apoptosis pathway [11]. A
variable number tandem repeat (VNTR) domain of MUC1
is immunogenic, which led to the establishment of mono-
clonal antibodies which react with the epitopes of the
domain. Monoclonal antibodies are used in the treatment of
many diseases such as osteoporosis, asthma, and hemato-
logical malignancies: Hodgkin’s lymphoma, chronic lym-
phocytic leukemia, or solid tumors [12]. The mechanism of
action of monoclonal antibodies that are used in tumor
therapy is based on the destruction of cancer cells by
inhibiting intracellular signal transduction which induces
the process of cell death. This process is performed by the
binding with tumor’s cells receptor and modulation of the
receptor, or interfering with ligand binding and/or dimer-
ization of the receptor [13]. Monoclonal antibodies may
also stimulate the host immune system through antibody-
dependent cell-mediated cytotoxicity (ADCC) or a com-
plement-dependent cytotoxicity (CDC) [14].
In recent years, in our laboratory we obtained a series of
novel amidine analogues of melphalan or chlorambucil
[15–17] and dinuclear platinum complexes with high
antitumor activity in human breast cancer cells [18, 19].
Our preliminary studies where we checked the combined
effects of a monoclonal antibody against MUC1 used
together with a novel dinuclear platinum complex (Pt12)
showed high anti-proliferative properties and a strong
cytotoxic activity in two breast cancer cell lines (MCF-7
and MDA-MB-231). This effect was much stronger than
the treatment with anti-MUC1, cisplatin, Pt12, or cisplatin
in the presence of anti-MUC1 [20]. A key element of the
research is to understand the molecular mechanisms of
apoptosis induced by anti-MUC1 in combination with the
new platinum complex in MDA-MB-231 cells. The breast
cancer cell line (MDA-MB-231) is characterized by inter-
mediate response to chemotherapy compared to MCF-7,
which is often chemotherapy responsive [21]. The purpose
of the study was to check the influence of monoclonal
antibody against MUC1 on sensitivity of MDA-MB-231
cells to chemotherapeutic agents (Pt12, cisplatin). We
decided to analyze the effect of such a treatment on
selected aspects of apoptosis: number of early and late
apoptotic cells, mitochondrial membrane potential (MMP),
DNA fragmentation, and concentration of apoptotic
markers (Bax, caspases-3, -8, -9).
Materials and methods
Materials
Dimethylformamide, K2PtCl4, KI, acetone, 4-ethylpyr-
idine, diethyl ether, methanol, cisplatin, monoclonal anti-
body anti-MUC1 GP1.4 were purchased from Sigma
Chemical Co. (USA). Stock cultures of human MDA-MB-
231 breast cancer cells were purchased from the American
Type Culture Collection (USA). Dulbecco’s minimal
essential medium (DMEM) and fetal bovine serum (FBS)
used in a cell culture were products of Gibco (USA).
Glutamine, penicillin, and streptomycin were obtained
from Quality Biologicals Inc. (USA). FITC Annexin V
Apoptosis Detection Kit II, JC-1 MitoScreen Kit, Apo-
Direct Kit were a product of BD Pharmigen. ELISA’s kits
were purchased from Uscn Life Science Inc. and
BioVendor. The chemical synthesis and structure of Pt12
was presented in publication [20].
Cell culture MDA-MB-231
Estrogen-negative breast cancer MDA-MB-231 cells were
maintained in DMEM (Dulbecco’s Minimal Essential
Medium) supplemented with 10 % FBS, 2 mM glutamine,
50 U/mL penicillin, 50 mg/mL streptomycin at 37 C in a
humidified atmosphere containing 5 % CO2. Cells were
incubated with anti-MUC1 (10 lg/mL), Pt12 (10 lM),
Pt12 ? anti-MUC1 (10 lM ? 10 lg/mL), cisplatin
(10 lM), cisplatin ? anti-MUC1 (10 lM ? 10 lg/mL)
for 24 and 48 h and used for further experiments such as
annexin V binding assay, determination of MMP and DNA
fragmentation. MDA-MB-231 cells after 24 h of incuba-
tion with compounds in the same concentrations were used
to prepare cell lysates. Briefly, trypsinized cells were
washed three times with cold PBS and centrifuged at
10009g for 5 min at 4 C. The cells (1 9 106) were sus-
pended in lysis buffer for whole cell lysates. After cen-
trifugation the supernatants were frozen immediately at
-70. The concentration of pro-apoptotic markers was
measured. Cells without addition of compounds were
treated as controls.
Annexin V binding assay
Apoptosis was determined assessing phosphatidylserine
exposure by Annexin V-FITC binding by means of the
FITC Annexin V Apoptosis Detection Kit II according to
the manufacturer’s instruction. Cells (10,000 cell mea-
sured) were analyzed in a flow cytometer (BD FACSCanto
II flow cytometer, CA, USA). Annexin V bounds with high
affinity to phosphatidylserine, and thus could be used to
identify cells in all stages of the programmed cell death
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[22]. Propidium iodide (PI) exclusively stained cells with a
disrupted cell membrane and could be used to identify late
apoptotic and dead cells. Cells cultured in a drug-free
medium were used as controls. Optimal parameter settings
were found using a positive control (cells incubated with
3 % formaldehyde in buffer during 30 min on ice). For-
ward scatter (FS) and side scatter (SC) signals were
detected on a logarithmic scale histogram. FITC was
detected in the FL1 channel (FL1 539; threshold-value 52).
Analysis was performed using the BD FACSCanto II flow
cytometer, and results were analyzed with FACSDiva
software (both from BD Biosciences Systems, San Jose,
CA, USA). Dots with Annexin V-/PI-(Q3), Annexin V?/
PI-(Q4), and Annexin V?/PI?(Q2) features represent
intact, early apoptotic, and necrotic cells, respectively. The
percent of apoptotic cells (early and late) were measured
as: percentage of cells from the upper right square (color
red) ? percentage of cells from the lower right square
(color blue).
Determination of mitochondrial membrane
potential
Disruption of the MMP was assessed using the lipophilic
cationic probe 5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenz-
imidazolcarbocyanine iodide (JC-1 MitoScreen kit; BD
Biosciences) as described previously [23]. Briefly, unfixed
cells were washed and resuspended in PBS supplemented
with JC-1. Cells were then incubated for 15 min at room
temperature (RT) in the dark, washed, and resuspended in
PBS for immediate BD FACSCanto II flow cytometry
analysis. The percentage of cells with disrupted MMP was
calculated in the FACSDiva software (both from BD
Biosciences Systems, San Jose, CA, USA).
DNA fragmentation assay
DNA fragmentation was examined by the terminal
deoxynucleotidyltransferase (TdT)-mediated dUTP nick
end labeling (TUNEL) method using a commercial assay
kit (APO-Direct Kit; BD Pharmingen, San Diego, CA,
USA). After treatment, cells were fixed with 1 %
paraformaldehyde in PBS (4 C, 30 min), washed in PBS,
and permeabilized with ice cold 70 % ethanol. The Apo-
Direct Kit-TUNEL assay was performed as described by
the manufacturer. Cells were analyzed in a BD FACSCanto
II flow cytometer. In total, 10,000 events were collected
per test sample. The results were analyzed in FACSDiva
software (both from BD Biosciences Systems, San Jose,
CA, USA). The percentage of TUNEL negative and posi-
tive cells was presented.
Determination of pro-apoptotic Bax protein
The high sensitivity assay kit (Uscn Life Sci Inc.) was
used to determine the concentration of pro-apoptotic Bax
protein in cell lysates. The microtiter plate provided has
been pre-coated with a monoclonal antibody specific to
Bax. Standards and samples were added to the appropriate
microtiter plate wells and incubated for 2 h at 37 C.
After first incubation step a biotin-conjugated polyclonal
antibody specific for Bax was pipetted and incubated for
1 h at 37 C. After washing away any unbound sub-
stances, avidin conjugated to horseradish peroxidase was
added to each microplate well and incubated. After
another aspiration and washing step a TMB substrate
solution was added to each well. The enzyme-substrate
reaction was terminated by the addition of a sulfuric acid
solution and the color change was measured at a wave-
length of 450 nm. The assay was performed in duplicate
and the concentration of Bax in the samples was then
determined by comparing the O.D. of the samples to the
standard curve. Range of the standard curve for Bax was
0.78–50 ng/mL. The minimum detectable dose of human
Bax was generally less than 0.32 ng/mL.
Determination of caspase-8 and caspase-9
Caspase-8 and caspase-9 concentrations in cell lysates
were determined using an enzyme-linked immunosorbent
assay kit (BioVendor). A monoclonal antibodies specific
for caspase-8 or caspase-9 have been pre-coated onto a
microplate. Standards and samples (100 lL each) were
pipetted into the wells in duplicate and antigen was bound
by the immobilized antibody. The working solution of
antibody was also added to all wells. Then the microplate
was incubated for 2 h at RT. After washing away any
unbound substances, an enzyme-linked polyclonal anti-
body specific for caspase-8 or caspase-9 (100 lL) was
added to each well for 1 h at RT. Following a wash to
remove any unbound antibody enzyme-reagent, a substrate
solution (100 lL) was added to the wells for 15 min; the
color developed in proportion to the amount of antigen
bound in the initial step. Color development was stopped
by phosphoric acid, and the intensity of the color was
measured at a wavelength of 450 nm. The minimum
detectable dose (MDD) of caspase-8 was 0.1 ng/mL and
caspase-9 was: 0.4 ng/mL. The concentrations of the
samples were calculated from the standard curve and ran-
ged from 0.16 to 10 ng/mL for caspase-8 and 1.6–100 ng/
mL for caspase-9. The results were presented in nanogram
per milliliter (ng/mL). There was no cross-reactivity with
other caspases.
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Determination of active caspase-3
The concentration of caspase-3 was checked using assay
kit from Uscn Life Sci Inc. Samples and standards
(100 lL/well) were added into wells and microplate was
incubated for 2 h at 37 C. After 2 h antibody (1:100) was
added and plate was incubated for next 60 min at 37 C.
The washing procedure was performed and polyclonal
antibody with enzyme was pipetted and kept for 30 min at
37 C. After washing away any unbound substances sub-
strate solution (90 lL/well) was added. The reaction was
stopped by the addition of sulfuric acid. The absorbance
was checked at the wavelength 450 nm. The concentration
of caspase-3 was calculated from standard curve
(0.156–10 ng/mL). The minimum detectable dose was
0.054 ng/mL. The results were presented in nanogram per
milliliter (ng/mL).
Statistical analysis
Experimental data were represented as mean ± SD since
each experiment was repeated three times. One-way
Anova, Dunnett’s multiple comparisons test was performed
to demonstrate the difference between control (untreated
cells) and the different treatments. A statistically
significant difference was defined at p\ 0.05. Statistical
analysis was performed using GraphPad Prism Version 6.0
(San Diego, CA, USA).
Results
To confirm that all tested compounds induced apoptosis in
MDA-MB-231 cells, several biochemical tests were done
such as flow cytometric analysis after annexin V-FITC and
PI staining, MMP, DNA fragmentation, and concentration
of pro-apoptotic factors.
Flow cytometry analysis allowed to detect apoptotic
cells (Annexin V?/PI-), life cells (Annexin V-/PI-), and
necrotic cells (Annexin V?/PI?) after 24 and 48 h of
incubation with drugs used in monotherapy (anti-MUC1,
cisplatin, Pt12) and in combination (cisplatin ? anti-
MUC1, Pt12 ? anti-MUC1) (Figs. 1, 2). The highest
number of early and late apoptotic cells was observed after
24 h of incubation with Pt12 and anti-MUC1 (34 %). The
value was higher compared to anti-MUC1 (11 %), cisplatin
(10 %), Pt12 (22 %), and cisplatin with anti-MUC1
(16 %). All values were significantly increased (p\ 0.05)
compared to control samples, in which the number of early
and late apoptotic cells reached 2 % (Fig. 1). After 48 h
Fig. 1 Flow cytometric analysis of breast cancer MDA-MB-231 cells
after incubation with anti-MUC1 (10 lg/mL), Pt12 (10 lM),
Pt12 ? anti-MUC1 (10 lM ? 10 lg/mL), cisplatin (10 lM), cis-
platin ? anti-MUC1 (10 lM ? 10 lg/mL) for 24 h and staining with
Annexin V and propidium iodide (PI). Dots with Annexin V-/
PI-(Q3), Annexin V?/PI-(Q4), and Annexin V?/PI?(Q2) features
represent intact, early apoptotic, and necrotic cells, respectively.
*p\ 0.05 versus control group
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the apoptotic effect increased significantly, especially after
combined treatment. We noticed that 51 % cells were in
early and late apoptosis after incubation with Pt12 and anti-
MUC1. The effect was stronger in comparison with
monotherapy anti-MUC1 (12 %), cisplatin (11 %), Pt12
(38 %), and cisplatin used in combination with anti-MUC1
(24 %). In control cells, we detected 7 % of apoptotic cells
(Fig. 2).
Loss of MMP (DWm) has been shown to be an early
event during apoptosis. To determine DWm, we used the
membrane potential-sensitive probe JC-1, which forms JC-
1 aggregates (with red color) at higher potential and JC-1
monomers (with green color) at low membrane potential,
and the ratio between the red and green signals is a measure
of DWm. The reduction of MMP is also associated with
appearance of cytochrome c in cytosol [24]. Pt12 with anti-
MUC1 reduced MMP in the highest rate. We observed that
51 % of cells had reduced DWm, whereas control cells only
4.1 %. The effect of reduction was weaker after 24 h of
incubation with agents used in monotherapy. Anti-MUC1,
cisplatin, Pt12 decreased the DWm in breast cancer cells to
18.2, 7.9, and 32.7 %. We observed that 21.8 % cells had
reduced DWm after incubation with cisplatin used together
with anti-MUC1 (Fig. 3). The stronger decrease was
noticed after 48 h of incubation with drugs. Pt12 and anti-
MUC1 caused the reduction of MMP in 57 % of breast
cancer cells. The weaker effect in reduction of DWm was
observed after monotherapy with anti-MUC1 (31.5 %),
cisplatin (18 %) and Pt12 (48.1 %). Cisplatin used with
anti-MUC1 decreased the MMP in 40.9 % cells (Fig. 4).
DNA degradation is one of the most characteristic
moments of programmed cell death. It was performed
using TUNEL assay. We observed TUNEL positive cells
(M2) with fragmented DNA. Cells with double stranded
DNA were called as TUNEL negative cells (M1). We
noticed that 29 % of cells were TUNEL positive after 24 h
of incubation with Pt12 and anti-MUC1. The DNA frag-
mentation was stronger than monotherapy by anti-MUC1
(8.1 %), cisplatin (5.2 %), Pt12 (21.2 %), and cisplatin
used together with anti-MUC1 (12.3 %). Only 0.6 % of
untreated cells had fragmented DNA (Fig. 5). After next
24 h of incubation, we observed that process of DNA
fragmentation was stronger, especially after Pt12 (10 lM)
with anti-MUC1 (10 lg/mL). We noticed that 93.4 % of
cells had degraded DNA. We proved that Pt12 with anti-
MUC1 were found to be more effective in degradation of
DNA compared to anti-MUC1, cisplatin, Pt12, and cis-
platin used in combination with anti-MUC1 (Fig. 6).
We measured the concentration of pro-apoptotic Bax
protein (Fig. 7), which is necessary to release the
Fig. 2 Flow cytometric analysis of breast cancer MDA-MB-231 cells
after incubation with anti-MUC1 (10 lg/mL), Pt12 (10 lM),
Pt12 ? anti-MUC1 (10 lM ? 10 lg/mL), cisplatin (10 lM), cis-
platin ? anti-MUC1 (10 lM ? 10 lg/mL) for 48 h and staining with
Annexin V and propidium iodide (PI). Dots with Annexin V-/
PI-(Q3), Annexin V?/PI-(Q4), and Annexin V?/PI?(Q2) features
represent intact, early apoptotic, and necrotic cells, respectively.
*p\ 0.05 versus control group
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cytochrome c from mitochondria to cytosol and improves
mitochondrial pathway of apoptosis. All examined com-
pounds significantly increased Bax concentration compared
to untreated cells. After 24 h of incubation with agents
used in monotherapy, the stronger inducer of Bax
releasement was Pt12 in dose 20 lM. The effect was
stronger than that produced by cisplatin and anti-MUC1
used alone. The highest increase in pro-apoptotic Bax
protein concentration was observed after combined treat-
ment of Pt12 (20 lM) together with anti-MUC1 (10 lg/
mL). The concentration of Bax was 145 ng/mL compared
to reference compound cisplatin used with anti-MUC1 in
the same doses, where the level of Bax was: 140 ng/mL.
The increase was almost 3 times stronger in comparison to
control, where cells were untreated.
Caspase-9 is a key component of mitochondrial pathway
of apoptosis. We determined the concentration of caspase-9
after monotherapy and combination treatment. We
observed that Pt12 was a stronger inducer of caspase-9
releasement compared to cisplatin and anti-MUC1 after
24 h of incubation with drugs. The strongest effect on
caspase-9 releasement was determined after combined
treatment with Pt12 (20 lM) and anti-MUC1 (10 lg/mL).
The concentration of caspase-9 was 39 ng/mL. After
cisplatin (20 lM) and anti-MUC1 (10 lg/mL) the level of
caspase-9 was 29 ng/mL (Fig. 8). Significant increase in
caspase-9 concentration was observed after combined
treatment with chemotherapeutic agents used in dose
20 lM and anti-MUC1 in dose 10 lg/mL (p\ 0.05).
We checked the effect of agents on apoptosis associated
with extrinsic pathway. Caspase-8 is a main mediator of
extrinsic pathway. All compounds increased the concen-
tration of caspase-8 compared to control value, but the
highest statistically significant increase was observed after
Pt12 (20 lM) and anti-MUC1 (10 lg/mL), in comparison
with cisplatin (20 lM) and anti-MUC1 (10 lg/mL), where
the concentrations were 1.02 and 0.86 ng/mL, respectively.
The effect was five times stronger compared with control
cells (Fig. 9).
Finally, we checked the concentration of caspase-3 in
cell lysates after 24 h of incubation with drugs used in
monotherapy and combination therapy (Fig. 10). The
concentration after Pt12 (20 lM), cisplatin (20 lM) was
3.9 versus 3.7 ng/mL. The strongest statistically significant
effect was observed after Pt12 (20 lM) with anti-MUC1
(4.4 ng/mL). Our results proved that combination therapy
is more effective strategy in increasing the levels of pro-
apoptotic markers compared to monotherapy.
Fig. 3 The loss of mitochondrial membrane potential of breast
cancer MDA-MB-231 cells after 24 h incubation with anti-MUC1
(10 lg/mL), Pt12 (10 lM), Pt12 ? anti-MUC1 (10 lM ? 10 lg/
mL), cisplatin (10 lM), cisplatin ? anti-MUC1 (10 lM ? 10 lg/
mL) as measured JC-1 fluorescence. X- and Y-axes are green and red
fluorescence, respectively. *p\ 0.05 versus control group. (Color
figure online)
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Discussion
Our preliminary studies showed that Pt2(4-ethylpyridine)4
(berenil)2 (Pt12) used together with anti-MUC1 antibody is
more cytotoxic than Pt12 alone or cisplatin with anti-
MUC1 in breast cancer MCF-7 and MDA-MB-231 cells.
The anti-proliferative effect of Pt12 with anti-MUC1 was
dependent on the estrogen receptor status of the breast
cancer cells [20]. Pt12 with anti-MUC1 was proved to be a
stronger inhibitor of collagen biosynthesis in breast cancer
cells compared to Pt12 alone and cisplatin with anti-
MUC1. Understanding the pathways by which Pt12 with
anti-MUC1 induces cell death can provide information
necessary to target-specific cell death pathways in the
treatment of breast cancer. In our study, the induction of
apoptosis by new platinum complex with anti-MUC1 in
human MDA-MB-231 breast cancer cells was confirmed
by several biochemical markers, such as phosphatidylser-
ine externalization, loss of MMP DWm, DNA degradation,
Bax, and caspase-3, -8, -9 levels. All compounds induced
apoptosis of breast cancer cells via mechanisms dependent
on caspases activation and associated with MMP disrup-
tion, but the strongest effect was observed after Pt12 used
in combination with anti-MUC1. In the literature appeared
some data about monoclonal antibodies against MUC1.
The positive results were obtained after the application of
anti-MUC1: C595, GP1.4, HMFG2, 90Y-muHMFG1, and
small molecule inhibitors GO-203 and PMIP [4]. The
antibody C595 is a murine antibody and it represents the
subclass of IgG3. C595 antibody and docetaxel strongly
induces apoptosis in ovarian cancer cells in vitro, and
in vivo inhibits tumor growth [25, 26]. GP1.4 antibody
inhibits proliferation and invasion of tumor cells. HMFG2
antibody also reduces tumor burden in a mouse model of
pancreatic cancer. Studies on 90Y-muHMFG1 antibody that
recognizes glycosylated extracellular MUC1 domain show
the long-term survival of people. Some antibodies suc-
cessfully completed preclinical phases. An example is a
HMFG1 antibody, which is currently in the third phase of
the clinical trial. MUC1 vaccine containing the cDNA (M-
FP) is also tested in the third phase of clinical trial in
patients with breast cancer [4]. The most promising is
combining monoclonal antibodies with chemotherapeutic
agents. Some studies on the use of other monoclonal
antibodies (trastuzumab, pertuzumab) and carboplatin in
the treatment of breast cancer is currently in phase II of
clinical trials called TRYPHAENA. In clinical trials, there
is also a 106 amino acid peptide against MUC1 used in
conjunction with the peptide HER-2/neu, and GM-CSF.
Moreover, Stimuvax which contains 25 amino acid
Fig. 4 The loss of mitochondrial membrane potential of breast cancer
MDA-MB-231 cells after 48 h incubation with anti-MUC1 (10 lg/mL),
Pt12 (10 lM), Pt12 ? anti-MUC1 (10 lM ? 10 lg/mL), cisplatin
(10 lM), cisplatin ? anti-MUC1 (10 lM ? 10 lg/mL) as measured
JC-1 fluorescence. X- and Y-axes are green and red fluorescence,
respectively. *p\ 0.05 versus control group. (Color figure online)
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Fig. 5 The DNA fragmentation of breast cancer MDA-MB-231 cells
after 24 h incubation with anti-MUC1 (10 lg/mL), Pt12 (10 lM),
Pt12 ? anti-MUC1 (10 lM ? 10 lg/mL), cisplatin (10 lM),
cisplatin ? anti-MUC1 (10 lM ? 10 lg/mL) as presented % of
TUNEL positive and negative cells. *p\ 0.05 versus control group
Fig. 6 The DNA fragmentation of breast cancer MDA-MB-231 cells
after 48 h incubation with anti-MUC1 (10 lg/mL), Pt12 (10 lM),
Pt12 ? anti-MUC1 (10 lM ? 10 lg/mL), cisplatin (10 lM),
cisplatin ? anti-MUC1 (10 lM ? 10 lg/mL) as presented % of
TUNEL positive and negative cells. *p\ 0.05 versus control group
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sequences and recognizes the protein core of MUC1 is
tested in the third phase of clinical trials [27]. All these
findings have provided the experimental basis for targeting
MUC1 in patients with diverse carcinomas (breast, pros-
tate, lung cancer, and others with epithelial origin) that
express this oncoprotein. According to the literature
MUC1-C protects against the apoptotic response to treat-
ment with diverse chemotherapeutic agents [9, 28–30]. The
anti-apoptotic effect might be associated with interaction
between MUC1-C and Bax protein. It leads to blockade of
Bax dimerization and releasement of cytochrome c. Our
results proved the highest levels of Bax protein after Pt12
and anti-MUC1 treatment compared with control. Uschida
et al. reported that inhibition of the MUC1-C oncoprotein
is synergistic with cytotoxic agents in the treatment of
breast cancer. They proved that combining MUC1-C
inhibitor (GO-203) with taxol or doxorubicin induced late
apoptosis/necrosis and activated caspase-3 and caspase-7 in
Fig. 7 The concentration of pro-apoptotic Bax protein in breast
cancer MDA-MB-231 cells after 24 h incubation with anti-MUC1
(10, 20 lg/mL), Pt12 (10, 20 lM), Pt12 ? anti-MUC1
(10 lM ? 10 lg/mL, 20 lM ? 10 lg/mL), cisplatin (10, 20 lM),
cisplatin ? anti-MUC1 (10 lM ? 10 lg/mL, 20 lM ? 10 lg/mL).
Data presented in ng/mL. *p\ 0.05 versus control group
Fig. 8 The concentration of caspase-9 in breast cancer MDA-MB-
231 cells after 24 h incubation with anti-MUC1 (10, 20 lg/mL), Pt12
(10, 20 lM), Pt12 ? anti-MUC1 (10 lM ? 10 lg/mL,
20 lM ? 10 lg/mL), cisplatin (10, 20 lM), cisplatin ? anti-MUC1
(10 lM ? 10 lg/mL, 20 lM ? 10 lg/mL). Data presented in ng/
mL. *p\ 0.05 versus control group
Fig. 9 The concentration of caspase-8 in breast cancer MDA-MB-
231 cells after 24 h incubation with anti-MUC1 (10, 20 lg/mL), Pt12
(10, 20 lM), Pt12 ? anti-MUC1 (10 lM ? 10 lg/mL,
20 lM ? 10 lg/mL), cisplatin (10, 20 lM), cisplatin ? anti-MUC1
(10 lM ? 10 lg/mL, 20 lM ? 10 lg/mL). Data presented in ng/
mL. *p\ 0.05 versus control group
Fig. 10 The concentration of caspase-3 in breast cancer MDA-MB-
231 cells after 24 h incubation with anti-MUC1 (10, 20 lg/mL), Pt12
(10, 20 lM), Pt12 ? anti-MUC1 (10 lM ? 10 lg/mL,
20 lM ? 10 lg/mL), cisplatin (10, 20 lM), cisplatin ? anti-MUC1
(10 lM ? 10 lg/mL, 20 lM ? 10 lg/mL). Data presented in ng/
mL. *p\ 0.05 versus control group
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ZR-75-1 cells [31]. Our research proved that combining
monoclonal antibody with potential chemotherapeutic
agent resulted in better pro-apoptotic activity. Pt12 with
anti-MUC1 activate both: extrinsic and intrinsic pathways
of programmed cell death, especially strongly induced
extrinsic pathway associated with caspase-8. The concen-
tration of caspase-8 was a few times stronger compared to
monotherapy. Monoclonal antibody against MUC1
increased sensitivity of breast cancer cells to the plat-
inum(II) compound. Taken together, combining antibodies
with drugs is more effective strategy in treatment of car-
cinoma with high expression of MUC1.
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